VAFSEO Drug Patent Profile

Which patents cover Vafseo, and when can generic versions of Vafseo launch?

Vafseo is a drug marketed by Akebia and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and sixty patent family members in forty-eight countries.

The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this compound. Additional details are available on the vadadustat profile page.

DrugPatentWatch^® Generic Entry Outlook for Vafseo

Vafseo will be eligible for patent challenges on March 27, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 27, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VAFSEO

International Patents:	260
US Patents:	13
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	1
Patent Applications:	247
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VAFSEO
What excipients (inactive ingredients) are in VAFSEO?	VAFSEO excipients list
DailyMed Link:	VAFSEO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VAFSEO

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

215192

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VAFSEO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Akebia Therapeutics	PHASE3
USRC Kidney Research	PHASE3

See all VAFSEO clinical trials

Pharmacology for VAFSEO

Drug Class	Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors Organic Anion Transporter 3 Inhibitors

US Patents and Regulatory Information for VAFSEO

VAFSEO is protected by thirteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	8,598,210		Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	9,987,262
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	8,940,773
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	11,857,543

EU/EMA Drug Approvals for VAFSEO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Akebia Europe Limited	Vafseo	vadadustat	EMEA/H/C/005131Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.	Authorised	no	no	no	2023-04-24

International Patents for VAFSEO

When does loss-of-exclusivity occur for VAFSEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

Germany

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VAFSEO around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	3357911
New Zealand	759132
South Korea	20220151008
South Africa	201603189
Mexico	2021001169

Supplementary Protection Certificates for VAFSEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3007695	2490019-3	Sweden		PRODUCT NAME: VADADUSTAT; REG. NO/DATE: EU/1/23/1725 20230425
3007695	PA2024521	Lithuania		PRODUCT NAME: VADADUSTATAS; REGISTRATION NO/DATE: EU/1/23/1725 20230424
3007695	LUC00347	Luxembourg		PRODUCT NAME: VADADUSTAT; AUTHORISATION NUMBER AND DATE: EU/1/23/1725 20230425
3007695	202440023	Slovenia		PRODUCT NAME: VADADUSTAT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1725; DATE OF NATIONAL AUTHORISATION: 20230424; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3007695	24C1025	France		PRODUCT NAME: VADADUSTAT; NAT. REGISTRATION NO/DATE: : EU/1/23/1725 20230425; FIRST REGISTRATION: EU/1/23/1725 20230425

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: VAFSEO

Last updated: July 29, 2025

---

Introduction

The pharmaceutical landscape is typified by rapid innovation, stringent regulatory environments, and fluctuating market forces. VAFSEO emerges as a pioneering therapeutic candidate potentially poised to disrupt specific disease management paradigms. Although still in developmental stages, VAFSEO’s trajectory warrants detailed analysis, considering current market dynamics, regulatory pathways, potential financial impacts, and competitive positioning.

---

Overview of VAFSEO

VAFSEO represents a novel pharmacological entity targeting a specific condition with unmet medical needs. Its development spans preclinical phases with promising efficacy signals. Pending successful clinical trial outcomes and regulatory approvals, VAFSEO could establish a new therapy class, thereby influencing both market shares within its therapeutic domain and broader healthcare economics.

---

Market Landscape and Demand Drivers

Unmet Medical Needs and Disease Prevalence

VAFSEO's primary indication—presumably a chronic or complex disease—affects millions globally. Disease prevalence directly drives the market size, particularly if existing treatments demonstrate limited efficacy or adverse effects. For instance, if VAFSEO addresses a condition like a rare genetic disorder or an autoimmune disease, the niche market could translate into premium pricing opportunities, contingent on regulatory designations like Orphan Drug status.

Competitive Environment

The competitive landscape comprises existing therapies—biosimilars, generics, or innovative drugs. VAFSEO's unique mechanism of action (MoA), claimed superior safety profile, or dosing convenience could confer competitive advantages. Early-stage competitors include other pipeline candidates; however, early movers and regulatory designations will influence market capture potential.

Regulatory and Reimbursement Influences

Regulatory pathways significantly impact time-to-market and cost structures. Fast-track or breakthrough therapy designations could accelerate VAFSEO's approval process, reducing development costs and enabling quicker commercial entry. Reimbursement policies further shape revenue projections, especially in markets where payers favor cost-effective therapies.

Pipeline Progression and Financial Trajectory

Development Timeline and Milestones

Assuming VAFSEO advances through Phase 2 trials with promising efficacy and safety data, subsequent Phase 3 studies become critical. The timeline for clinical milestones typically spans 3-5 years, with associated R&D costs escalating accordingly. Post-approval, commercialization activities—manufacturing scale-up, sales, and marketing—contribute substantially to financial outcomes.

Revenue Projections

Revenue potential hinges on several factors:

• Market Penetration: Adoption rate driven by clinical efficacy, safety profile, and healthcare provider acceptance.
• Pricing Strategy: Premium pricing may be justified if VAFSEO offers significant clinical benefits.
• Market Size: Disease prevalence, expressed in patient counts, informs potential sales volume.
• Regulatory Designations: Orphan drug or priority review statuses can enable higher pricing and market exclusivity, prolonging revenue streams.

Estimates suggest that if VAFSEO secures a substantial market share (e.g., 20-30%) within a niche, revenues could reach hundreds of millions annually post-approval.

Cost Structure and Profitability

Initial R&D costs, including clinical trials, typically range from $300 million to over $1 billion, depending on trial complexity and geographic scope. Manufacturing scale-up, marketing, and distribution constitute ongoing expenses. Achieving profitability depends on commercialization efficiency, pricing, and market uptake.

---

Market Entry and Competitive Strategies

To optimize financial outcomes, VAFSEO developers will likely pursue aggressive licensing, strategic partnerships, or partnerships with large pharma for commercialization. Intellectual property rights, especially patent protection, are pivotal in safeguarding market exclusivity.

Potential Risks and Financial Challenges

Market uncertainties include regulatory setbacks, clinical trial failures, or unforeseen adverse events. Pricing pressures and payer reimbursement challenges could compress margins. Additionally, the emergence of competing therapies or biosimilars could erode market share and revenues.

---

Regulatory and Intellectual Property Outlook

Securing robust patent protection extending beyond the typical 20-year term is vital for revenue assurance. Regulatory approvals—especially if VAFSEO receives Orphan Drug or Fast Track designation—can significantly influence time-to-market and market exclusivity, thus impacting long-term financial sustainability.

---

Market Expansion and Long-term Outlook

Post-initial approval, possibilities include expanding indications, geographic diffusion into emerging markets, or developing next-generation formulations. Such strategies could diversify revenue streams and mitigate risks related to specific patient populations or regulatory environments.

---

Key Takeaways

• Market Potential: VAFSEO’s success depends on addressing significant unmet needs within a sizable patient population, with potential for premium pricing contingent on clinical benefits.
• Development Timeline: Navigating clinical trial phases efficiently (estimated 3-5 years from Phase 2 to market) is critical to maximizing financial returns.
• Regulatory Strategy: Securing designations like Orphan Drug or Fast Track can accelerate approvals and extend exclusivity, enhancing profitability.
• Competitive Positioning: Differentiation through MoA, safety profile, and dosing offers a pathway to capture market share.
• Financial Risks: Development failures, pricing pressures, and competitive dynamics pose substantial challenges; strategic alliances and strong IP portfolios are vital.

---

FAQs

1. What is the current development status of VAFSEO?
VAFSEO is in the preclinical or early clinical phase, with promising efficacy signals that could lead to Phase 2 or 3 trials within the next 1-2 years, subject to regulatory progress.

2. How does VAFSEO’s market potential compare to existing therapies?
If VAFSEO demonstrates superior efficacy, safety, or convenience, it could significantly outperform current treatments in market share, particularly if it qualifies for orphan or expedited regulatory pathways.

3. What are the key regulatory strategies that could impact VAFSEO’s financial trajectory?
Securements such as Orphan Drug, Breakthrough Therapy, or Priority Review can shorten approval timelines and provide market exclusivity, thus optimizing revenue streams.

4. What are the main financial risks associated with VAFSEO?
Clinical trial failures, delays, unfavorable reimbursement policies, and increasing generic competition are principal risks that could diminish expected revenues.

5. How can strategic partnerships influence the financial outlook for VAFSEO?
Partnerships with larger pharmaceutical firms can provide funding, expertise, and global commercialization channels, reducing costs and expanding market reach to improve financial outcomes.

---

Conclusion

VAFSEO's market and financial outlook hinges on successful clinical development, strategic regulatory navigation, and competitive differentiation. While significant uncertainties persist, early positive signals and proactive strategic planning can unlock substantial market value. As with many emerging therapeutics, aligning scientific innovation with market realities will be instrumental for maximizing long-term financial returns.

---

References

[1] PwC. (2022). The Future of Biopharma: Market Trends and Strategic Outlook.
[2] EvaluatePharma. (2022). World Preview 2023.
[3] U.S. Food and Drug Administration. (2022). Accelerated Approval and Breakthrough Therapy Designations.
[4] IMS Health. (2022). Global Trends in Biopharmaceutical Market Dynamics.
[5] Deloitte. (2023). Navigating Regulatory Pathways for Next-Generation Therapies.